Search results for "hepatitis B virus"

showing 10 items of 295 documents

Hepatitis B vaccination of relatives of hepatitis B virus DNA positive carriers: an experience with plasma-derived vaccine.

1989

We assessed in a western population the efficacy of a plasma-derived hepatitis B vaccine in relatives of highly infectious hepatitis B virus (HBV) carriers. A consecutive group of 103 HbsAg, anti-HBs and anti-HBc negative household relatives of 45 HBV-DNA positive chronic carriers received a 5 micrograms dose of plasma-derived vaccine at 0, 1, 2 and 12 months. Protective levels of immunity developed in 101 subjects (97.8%) 3 months after boosting. Low responders to the vaccine were mostly found among parents and spouses of carriers, whilst offspring and siblings were usually high responders. The main discriminant in predicting a good response was age below 12 years. Hyporesponsiveness did n…

AdultViral Hepatitis VaccinesHBsAgHepatitis B vaccineEpidemiologyPopulationmedicine.disease_causeImmune systemImmunityRisk FactorsMedicineHumansHepatitis B VaccinesHepatitis B AntibodieseducationHepatitis B viruseducation.field_of_studyHepatitis B Surface Antigensbusiness.industryInfant Newbornvirus diseasesInfantHepatitis Bmedicine.diseaseHepatitis BVirologyHepatitis B Core Antigensdigestive system diseasesVaccinationImmunologyCarrier StatebusinessDNA ProbesEuropean journal of epidemiology
researchProduct

Assessment of determinants affecting the dual topology of hepadnaviral large envelope proteins

2004

For functional diversity, the large (L) envelope protein of hepatitis B virus (HBV) acquires a dual transmembrane topology via co-translational membrane integration of the S region and partial post-translational translocation of the preS subdomain. Because each process requires the second transmembrane segment (TM2), we explored the action of this determinant by using protease protection analysis of mutant L proteins. We demonstrated that neither the disruption of a leucine zipper-like motif by multiple alanine substitutions nor the flanking charges of TM2 affected the topological reorientation of L. The dispensability of both putative subunit interaction modules argues against a link betwe…

AlanineHepatitis B virusHepatitis B virusVirus AssemblyAmino Acid MotifsMolecular Sequence DataProtein domainPhenotype mixingBiological TransportBiologyEndoplasmic Reticulummedicine.disease_causeVirologyTransmembrane domainDual topologyAmino Acid SubstitutionViral Envelope ProteinsVirologyMembrane topologymedicineHepadnavirusAmino Acid SequenceProtein Processing Post-TranslationalJournal of General Virology
researchProduct

Secretion and antigenicity of hepatitis B virus small envelope proteins lacking cysteines in the major antigenic region.

1995

Abstract Disulfide bonds are of crucial importance for the structure and antigenic properties of the hepatitis B virus (HBV) envelope. We have evaluated the role of the eight highly conserved cysteines of the major antigenic region for assembly, secretion, and antigenicity of the envelope proteins. Mutants carrying single or multiple substitutions of alanine for cysteine were analyzed using epitope tagging and transient expression in COS-7 cells. The only single cysteines found to be indispensable for efficient secretion were Cys-107 and Cys-138, but double mutation of Cys-137 and Cys-139 also created a block to secretion. Poorly secreted mutants formed aberrant oligomeric structures. The a…

AntigenicityHepatitis B virusGlycosylationmedicine.drug_classMutantMolecular Sequence DataBiologymedicine.disease_causeMonoclonal antibodyEpitopeCell LineViral Envelope ProteinsVirologymedicineAnimalsSecretionCysteineDisulfidesHepatitis B virusAlanineImmunoassayHepatitis B Surface AntigensBase SequenceAntibodies MonoclonalOligonucleotides AntisenseHepatitis BMolecular biologyBiochemistryMutagenesis Site-DirectedCysteineVirology
researchProduct

Mosaic Qβ coats as a new presentation model

1998

The new protein carrier was developed on the basis of recombinant RNA phage Qbeta capsid. C-terminal UGA extension of the short form of Qbeta coat, so-called A1 extension, served as a target for presentation of foreign peptides on the outer surface of mosaic Qbeta particles. In conditions of enhanced UGA suppression, the proportion of A1-extended to short coats in mosaic particles dropped from 48% to 14%, with an increase of the length of A1 extension. A model insertion, short preS1 epitope 31-DPAFR-35 of hepatitis B surface antigen, demonstrated superficial location on the mosaic Qbeta particles and ensured specific antigenicity and immunogenicity.

AntigenicityRecombinant Fusion ProteinsGenetic VectorsBiophysicsBiologyHepatitis b surface antigenBiochemistryEpitopelaw.inventionCapsid assemblyMiceCapsidPhage QβPeptide LibraryStructural BiologylawGeneticsAnimalsHepatitis B virus preS1Cloning MolecularMolecular BiologyAllolevivirusMice Inbred BALB CCoat protein UGA suppressionVirus AssemblyImmunogenicityA1 extensionRNACell BiologyImmunogenicityVirologyMolecular biologyCapsidCarrier proteinCodon TerminatorRecombinant DNACapsid ProteinsFEBS Letters
researchProduct

Duck Hepatitis B Virus Requires Cholesterol for Endosomal Escape during Virus Entry

2008

ABSTRACT The identity and functionality of biological membranes are determined by cooperative interaction between their lipid and protein constituents. Cholesterol is an important structural lipid that modulates fluidity of biological membranes favoring the formation of detergent-resistant microdomains. In the present study, we evaluated the functional role of cholesterol and lipid rafts for entry of hepatitis B viruses into hepatocytes. We show that the duck hepatitis B virus (DHBV) attaches predominantly to detergent-soluble domains on the plasma membrane. Cholesterol depletion from host membranes and thus disruption of rafts does not affect DHBV infection. In contrast, depletion of chole…

AvihepadnavirusbiologyvirusesImmunologyDuck hepatitis B virusBiological membraneEndosomesVirus Internalizationbiology.organism_classificationMicrobiologyVirologyVirusHepatitis B Virus DuckVirus-Cell InteractionsCholesterolViral envelopeHepadnaviridaeViral entryCell Line TumorVirologyInsect ScienceHepatocytesHumanslipids (amino acids peptides and proteins)Lipid raftJournal of Virology
researchProduct

DNA-mediated immunization to hepatitis B virus envelope proteins: preS antigen secretion enhances the humoral response.

1999

In order to design optimized DNA vectors as genetic vaccines against infections with the hepatitis B virus (HBV) we investigated if secretion or retention of the viral antigens has an influence on the quality and quantity of the humoral immune response. Intramuscular injection of plasmid DNA encoding the HBV large L envelope protein, known to be retained within host cells, induced only a weak response in mice whereas a vector expressing the secretion-competent small S envelope protein elicited strong and sustained immunity. Immunization with rearranged envelope genes further demonstrated that secretion affects the magnitude of the immune response. In situ expression of modified small and mi…

Biologymedicine.disease_causeEpitopeVirusMiceImmune systemAntigenAdjuvants ImmunologicViral Envelope ProteinsmedicineVaccines DNAAnimalsHepatitis B VaccinesHepatitis B AntibodiesProtein PrecursorsHepatitis B virusMice Inbred BALB CHepatitis B Surface AntigensGeneral VeterinaryGeneral Immunology and MicrobiologyImmunogenicityPublic Health Environmental and Occupational HealthVirologyMolecular biologyInfectious DiseasesHumoral immunityCOS Cellsbiology.proteinMolecular MedicineFemaleAntibodyVaccine
researchProduct

Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice

2015

Abstract Background Therapeutic vaccination is a novel treatment approach for chronic hepatitis B, but only had limited success so far. We hypothesized that optimized vaccination schemes have increased immunogenicity, and aimed at increasing therapeutic hepatitis B vaccine efficacy. Methods Modified Vaccinia virus Ankara (MVA) expressing hepatitis B virus (HBV) antigens was used to boost protein-prime vaccinations in wildtype and HBV-transgenic (HBVtg) mice. Results Protein-prime/MVA-boost vaccination was able to overcome HBV-specific tolerance in HBVtg mice with low and medium but not with high antigenemia. HBV-specific antibody titers, CD8+ T-cell frequencies and polyfunctionality inverse…

CD4-Positive T-Lymphocytes0301 basic medicineHBsAgHepatitis B vaccineImmunization SecondaryMice TransgenicVaccinia virusCD8-Positive T-Lymphocytesmedicine.disease_cause03 medical and health scienceschemistry.chemical_compoundAntigenNeutralization TestsImmune ToleranceAnimalsMedicineHepatitis B VaccinesHepatitis B e AntigensHepatitis B AntibodiesHepatitis B virusHepatitis B Surface AntigensGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityPublic Health Environmental and Occupational Healthvirus diseasesHepatitis BHepatitis Bmedicine.diseaseAntibodies NeutralizingHepatitis B Core AntigensVirologyMice Inbred C57BLVaccination030104 developmental biologyInfectious DiseaseschemistryImmunologyMolecular MedicineVacciniabusinessVaccine
researchProduct

Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus hepatitis B virus mut…

1995

To assess the significance of cell-mediated immunity, T cells were derived from the peripheral blood and liver tissue of hepatitis B virus (HBV)-infected patients and controls. The analysis of the 3H-thymidine-uptake in response to a panel of recombinant HBV antigens revealed that peripheral blood mononuclear cells (PBMC) of the 25 viremic patients with inflammatory active, chronic hepatitis B, 16 with wild-type and nine with HBe-minus HBV mutant infection, showed stronger proliferative responses to HBc and HBe antigens than 16 asymptomatic nonviremic HBsAg carriers with normal aminotransferase levels (HBc: SI 19.3 +/- 3.9 vs. 13.0 +/- 3.2 vs. 8.0 +/- 1.2; P.01 and HBe: SI 16.6 +/- 4.0 vs. …

CD4-Positive T-LymphocytesHBsAgHepatitis B virusmedicine.disease_causeVirusAntigenmedicineHumansHepatitis B e AntigensHepatitis B virusHepatologybiologybusiness.industryvirus diseasesInterferon-alphaHepatitis Bmedicine.diseasebiology.organism_classificationHepatitis BVirologyHepatitis B Core Antigensdigestive system diseasesHBcAgHBeAgHepadnaviridaeImmunologyChronic DiseaseMutationbusinessCell DivisionHepatology (Baltimore, Md.)
researchProduct

Molecular Basis for the Interaction of the Hepatitis B Virus Core Antigen with the Surface Immunoglobulin Receptor on Naive B Cells

2001

ABSTRACTThe nucleocapsid of the hepatitis B virus (HBV) is composed of 180 to 240 copies of the HBV core (HBc) protein. HBc antigen (HBcAg) capsids are extremely immunogenic and can activate naive B cells by cross-linking their surface receptors. The molecular basis for the interaction between HBcAg and naive B cells is not known. The functionality of this activation was evidenced in that low concentrations of HBcAg, but not the nonparticulate homologue HBV envelope antigen (HBeAg), could prime naive B cells to produce anti-HBc in vitro with splenocytes from HBcAg- and HBeAg-specific T-cell receptor transgenic mice. The frequency of these HBcAg-binding B cells was estimated by both hybridom…

CD4-Positive T-LymphocytesImmunologyNaive B cellAntigen presentationMolecular Sequence DataImmunoglobulin Variable RegionMice Transgenicmedicine.disease_causeAntibodies ViralMicrobiologyMiceAntigenVirologymedicineAnimalsHumansAmino Acid SequenceReceptors ImmunologicHepatitis B virusAntigen PresentationB-LymphocytesMice Inbred BALB Cbiologyvirus diseasesAntibodies MonoclonalVirologyMolecular biologyHepatitis B Core Antigensdigestive system diseasesPeptide FragmentsVirus-Cell InteractionsHBcAgHBeAgImmunoglobulin MImmunoglobulin MInsect Sciencebiology.proteinMice Inbred CBAImmunoglobulin Light ChainsBinding Sites AntibodyAntibodyImmunoglobulin Heavy ChainsSequence Alignment
researchProduct

Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the…

2011

Abstract Strategies for antibody-mediated cancer immunotherapy, such as active immunization with virus-like particle (VLP)-based vaccines, are gaining increasing attention. We developed chimeric hepatitis B virus core antigen (HBcAg)-VLPs that display a surface epitope of the highly selective tumor-associated cell lineage marker claudin-18 isoform 2 (CLDN18.2) flanked by a mobility-increasing linker. Auto-antibodies elicited by immunization with these chimeric HBcAg-VLPs in 2 relevant species (mouse and rabbit) bind with high precision to native CLDN18.2 at physiologic densities on the surface of living cells but not to the corresponding epitope of the CLDN18.1 splice variant that differs b…

Cancer ResearchHepatitis B virusLung Neoplasmsmedicine.medical_treatmentMolecular Sequence DataCHO CellsAdenocarcinomaActive immunizationCancer VaccinesEpitopeMiceCricetulusAntigenVirus-like particleCancer immunotherapyAntibody SpecificityStomach NeoplasmsCell Line TumorCricetinaemedicineAnimalsHumansProtein IsoformsAmino Acid SequenceVaccines Virus-Like ParticleAutoantibodiesMice Inbred BALB Cbiologybusiness.industryAntibody-Dependent Cell CytotoxicityMembrane ProteinsVirologyMolecular biologyHepatitis B Core AntigensHBcAgHEK293 CellsOncologyCell cultureClaudinsbiology.proteinRabbitsAntibodybusinessCancer research
researchProduct